Kopran

Price chart

Previous close

₹263.20

Open

₹261.00

Day high

₹271.53

Day low

₹261.00

Listed on NSE since 9 June 1999.

Market value

₹1,271.94 Cr

P/E (trailing)

50.91

EPS (trailing)

₹5.17

Price to book

2.40

Dividend yield

1.24%

Debt to equity

0.29

Profit margin

3.6%

Beta

1.01

Volume today

1.44 L

Average volume

10.49 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: Kopran’s results filed with NSE, consolidated (the whole group). Net profit is the share of Kopran’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Kopran’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, penicillin, quinolone, anti-protozoal, sulphonamides, respiratory, tetracycline, cardiovascular, anti-diabetic, urology, pain management and anti-inflammatory, gastrointestinal, erectile dysfunction, anthemintic, anti-allergic, central nervous system, anti-malarial, anti-thyroid, and carbapenems. In addition, the company offers drugs for anti-hypertensive, neuromodulator, anti-acne, anti-infective, antibiotic, anti-thrombotic, anti-diabetic, anti-asthamatic, antihyperlipidemic, anti-convulsants, anti-anxiety, pulmonary arterial hypertension, chronic heart failure, neuropathic pain, and erosive esophagitis. Kopran Limited was incorporated in 1958 and is based in Mumbai, India.

Industry

Drug Manufacturers - General

Based in

Mumbai

Employees

1,156

Company website · Profile: Yahoo Finance

No headlines name Kopran in the last day or two.

• Dividend - Rs 3 Per Share

  Dividend · ex-date 11 August 2026

• Dividend - Rs 3 Per Share

  Dividend · ex-date 4 September 2025

• Annual General Meeting/Dividend - Rs 3 Per Share

  Dividend · ex-date 2 September 2024

• Annual General Meeting/Dividend - Rs 3 Per Share

  Dividend · ex-date 7 September 2023

• Dividend - Rs 3 Per Share

  Dividend · ex-date 4 August 2022

• Dividend - Rs 1.50 Per Share

  Dividend · ex-date 5 August 2021

• Interim Dividend - Rs 1.50 Per Share

  Dividend · ex-date 5 November 2020 · record date 7 November 2020

• Annual General Meeting

  Action · ex-date 3 September 2020

Source: NSE. Latest first, 8 of 20.